人乳头瘤病毒可检测性与宫颈癌预后:系统综述与Meta分析
该研究系统检索EMBASE和MEDLINE至2022年1月27日,纳入77项研究,评估治疗前HPV检测阳性与宫颈癌复发及无病、癌症特异性、总生存的关系。HPV阳性与更好的无病生存(HR 0.38,95%CI 0.25-0.57)、癌症特异性生存(HR 0.56,95%CI 0.44-0.71)和总生存(HR 0.59,95%CI 0.47-0.74)相关,但与复发无显著关联(HR 0.59,95%CI 0.33-1.07)。
要点
- 治疗前HPV检测阳性与宫颈癌更好的无病生存、癌症特异性生存和总生存相关。
- HPV阳性与复发无显著关联(HR 0.59,95%CI 0.33-1.07)。
- Meta回归显示病例数、肿瘤分级、标本类型、基因靶点和HPV患病率共同解释73.8%的异质性。
核心结论
- 本综述表明宫颈癌中HPV可检测性与更好的临床预后相关。
研究设计与样本
- 系统综述与Meta分析,检索EMBASE和MEDLINE从建库至2022年1月27日,纳入77项研究。
- 纳入研究需评估治疗前宫颈活检或细胞中HPV DNA或RNA,样本量≥20例侵袭性宫颈癌患者,并报告HPV阳性或阴性对复发、无病生存、癌症特异性生存或总生存的影响。
- 采用随机效应模型合并风险比(HR)和95%CI,并进行Meta回归探索异质性。
主要发现
- HPV检测阳性与更好的无病生存相关(HR 0.38,95%CI 0.25-0.57;15项研究,2,564例)。
- HPV检测阳性与更好的癌症特异性生存相关(HR 0.56,95%CI 0.44-0.71;9项研究,1,398例)。
- HPV检测阳性与更好的总生存相关(HR 0.59,95%CI 0.47-0.74;36项研究,9,169例)。
- HPV检测阳性与复发无显著关联(HR 0.59,95%CI 0.33-1.07;8项研究,1,313例)。
- Meta回归显示病例数、肿瘤分级、标本类型、基因靶点和HPV患病率共同解释73.8%的研究间异质性。
关键数值与推荐
- 在77项研究中,30项报告HPV状态与组织学的关系,39项与癌症分期,13项与肿瘤分级,17项与肿瘤大小,23项与淋巴结受累,4项与治疗反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether testing positive for human papillomavirus (HPV) before treatment is associated with cervical cancer recurrence and disease-free, cancer-specific, and overall survival and to report the relationship of HPV to cervical cancer histology, stage, grade, tumor size, lymph node involvement, and treatment response. DATA SOURCES: EMBASE and MEDLINE were searched from inception to January 27, 2022, with the use of MeSH terms and keywords relating to cervical cancer, HPV, and prognosis. ClinicalTrials.gov was not searched because of the nature of our review question. METHODS OF STUDY SELECTION: Studies must have assessed HPV DNA or RNA in cervical pretreatment biopsies or cells from 20 or more patients with invasive cervical cancer followed up for any length of time and reported the effect of testing positive or negative for HPV on cervical cancer recurrence, disease-free survival, cancer-specific survival, or overall survival. We extracted data on HPV-detection methods, patient and tumor characteristics, and clinical outcomes. TABULATION, INTEGRATION, AND RESULTS: Hazard ratios (HRs) and 95% CIs were pooled with a random-effects model. Meta-regression was performed to explore heterogeneity. Of 11,179 titles or abstracts and 474 full-text articles reviewed, 77 studies were included in the systematic review. Among these 77 studies, 30 reported on the relationship of HPV status to histology, 39 to cancer stage, 13 to tumor grade, 17 to tumor size, 23 to lymph node involvement, and four to treatment response. Testing positive for HPV was associated with better disease-free survival (HR 0.38, 95% CI 0.25-0.57; 15 studies with 2,564 cases), cancer-specific survival (HR 0.56, 95% CI 0.44-0.71; nine studies with 1,398 cases), and overall survival (HR 0.59, 95% CI 0.47-0.74; 36 studies with 9,169 cases), but not recurrence (HR 0.59, 95% CI 0.33-1.07; eight studies with 1,313 cases). Meta-regression revealed that the number of cases, tumor grade, specimen type, gene target, and HPV prevalence together explained 73.8% of the between-study heterogeneity. CONCLUSION: This review indicates that HPV detectability in cervical cancer is associated with a better clinical prognosis. SYSTEMATIC REVIEW REGISTRATION: https://osf.io/dtyeb .
引用
- Volesky-Avellaneda KD, Laurie C, Tsyruk-Romano O, et al. Human Papillomavirus Detectability and Cervical Cancer Prognosis: A Systematic Review and Meta-analysis. Obstet Gynecol. 2023. PMID: 37856917. doi:10.1097/AOG.0000000000005370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。